Eyepoint Pharmaceuticals LUGANO Phase 3 results point to new treatment options for wet AMD

Eyepoint Pharmaceuticals LUGANO Phase 3 results point to new treatment options for wet AMD
Eyepoint LUGANO results steer focus

Eyepoint Pharmaceuticals has released the results of its LUGANO Phase 3 clinical trial, bringing renewed attention to treatment prospects for patients suffering from wet age-related macular degeneration (AMD).

Company Chief Strategic Science Officer Dr. Tarek Hassan detailed the outcomes during 'The Spotlight Series', highlighting key data insights and indicating anticipation for further advancements as the focus moves to the upcoming LUCIA trial. The company remains optimistic about its pipeline in retinal disease, aiming to deliver meaningful improvements for wet AMD patients.

Eyepoint previously released topline results from its pivotal Phase 3 LUGANO trial of DURAVYU for wet AMD treatment, according to company disclosures. The company also reported promising LUGANO trial results for sustained release TKIs in wet AMD treatment in a separate update last year. The latest announcement continues a series of data releases focused on expanding retinal disease therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.